Yet another interesting article, just published Ju

Yet another interesting article, just published June 30, 2022, from another board.

"In the need of reinforcing the drug repositioning strategy
and developing specific SARS-CoV-2 treatment, recently,
three main groups of scientists discovered that a new
antibacterial drug, named brilacidin, provides attractive
benefits against SARS-CoV-2, and specifically without
major side effects.
This previous findings were confirmed by Xu, et al. [2],
who further, specified that the protective effect of brilacidin
is more likely to be preventive than curative, as brilacidin
has no inhibition/protective effect after SARS-CoV-2-cell
attachment, but only can inhibit SARS-CoV-2 entry into
cells.
Furthermore, while Xu, et al. [2] demonstrated the
effectiveness of brilacidin against SARS-CoV-2 and its
derivative variants including P.1 and B.1.1.7 strains, Hu, et
al. [3] discovered that brilacidin protective activity has a
broader spectrum to other sarbecoviruses, including OC43,
229E, and NL63 strains.
Highlights
1. Brilacidin protects cells from SARS-Co-2 infection,
at low dose.
2. Brilacidin has a broad-spectrum antiviral activity
against multiple Human Coronaviruses (HCoVs)
including SARS-CoV-2 and its derivatives, HCoV-
229E, HCoV-OC43, and HCoV-NL63.
3. Brilacidin has a dual antiviral mechanism of
action, including virucidal activity and binding to
coronavirus attachment factor HSPGs on the host
cell surface.

https://www.jelsciences.com/articles/jbres1504.pdf